{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:44:55Z","timestamp":1792025095847,"version":"4.4.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chikungunya vaccine recommendations remain controversial. CHIK-LA has lost its US approval. Adequate data on human vaccine efficacy for either vaccine is lacking. Live virus vaccines have inherent risks. Given early safety signals for CHIK-LA, a robust human safety dataset is lacking.<\/jats:p>","DOI":"10.1093\/infdis\/jiag284","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:42:25Z","timestamp":1779968545000},"page":"508-512","source":"Crossref","is-referenced-by-count":0,"title":["Chikungunya Vaccines for Travelers: Unanswered Pragmatic Questions Persist"],"prefix":"10.1093","volume":"234","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5642-5257","authenticated-orcid":false,"given":"David O","family":"Freedman","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, University of Alabama at Birmingham , Birmingham, Alabama ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"2026101419582247100_jiag284-B1","author":"World Health Organization"},{"key":"2026101419582247100_jiag284-B2","doi-asserted-by":"crossref","first-page":"taad008","DOI":"10.1093\/jtm\/taad008","article-title":"Chikungunya: risks for travellers","volume":"3","author":"Simon","year":"2023","journal-title":"J Travel Med"},{"key":"2026101419582247100_jiag284-B3","doi-asserted-by":"crossref","first-page":"taaf118","DOI":"10.1093\/jtm\/taaf118","article-title":"Chikungunya vaccination for travellers: practical guidance for clinical decision-making","volume":"32","author":"Hills","year":"2025","journal-title":"J Travel Med"},{"key":"2026101419582247100_jiag284-B4"},{"key":"2026101419582247100_jiag284-B5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1473-3099(25)00680-2","article-title":"Chikungunya adolescent vaccination and the distinct risk-benefit landscapes","volume":"26","author":"Marques","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"2026101419582247100_jiag284-B6","author":"Advisory Committee on Immunization Practices"},{"key":"2026101419582247100_jiag284-B7","author":"UK Department of Health & Social Care"},{"key":"2026101419582247100_jiag284-B8","author":"Medicines and Healthcare products Regulatory Agency (MHRA)"},{"key":"2026101419582247100_jiag284-B9","author":"Robert Koch Institute"},{"key":"2026101419582247100_jiag284-B10","doi-asserted-by":"crossref","first-page":"101498","DOI":"10.1016\/j.coviro.2025.101498","article-title":"A storm is born: immune activation and pathogenesis in arthritogenic alphavirus infections","volume":"74","author":"Freppel","year":"2026","journal-title":"Curr Opin Virol"},{"key":"2026101419582247100_jiag284-B11","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3390\/v17111469","article-title":"The role of innate cells during alphavirus chikungunya infection","volume":"17","author":"Silva","year":"2025","journal-title":"Viruses"},{"key":"2026101419582247100_jiag284-B12","doi-asserted-by":"crossref","first-page":"128251","DOI":"10.1016\/j.vaccine.2026.128251","article-title":"Vaccination against chikungunya\u2014a systematic review on the immunogenicity, tolerability, and safety of the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya","volume":"75","author":"Kling","year":"2026","journal-title":"Vaccine"},{"key":"2026101419582247100_jiag284-B13","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40259-024-00677-y","article-title":"Chikungunya virus vaccines: a review of IXCHIQ and PXVX0317 from pre-clinical evaluation to licensure","volume":"38","author":"Weber","year":"2024","journal-title":"BioDrugs"},{"key":"2026101419582247100_jiag284-B14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1473-3099(24)00510-3","article-title":"First immunogenicity and safety data on live chikungunya vaccine in an endemic area","volume":"25","author":"Freedman","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026101419582247100_jiag284-B15","doi-asserted-by":"crossref","first-page":"taaf039","DOI":"10.1093\/jtm\/taaf039","article-title":"A new non-live chikungunya vaccine for travellers","volume":"32","author":"Freedman","year":"2025","journal-title":"J Travel Med"},{"key":"2026101419582247100_jiag284-B16","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(25)00372-1","article-title":"Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial","volume":"405","author":"Tindale","year":"2025","journal-title":"Lancet"},{"key":"2026101419582247100_jiag284-B17","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0140-6736(25)00345-9","article-title":"Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo controlled trial","volume":"405","author":"Richardson","year":"2025","journal-title":"Lancet"},{"key":"2026101419582247100_jiag284-B18","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(23)00641-4","article-title":"Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"401","author":"Schneider","year":"2023","journal-title":"Lancet"},{"key":"2026101419582247100_jiag284-B19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1473-3099(25)00631-0","article-title":"Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil","volume":"26","author":"Buerger","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"2026101419582247100_jiag284-B20","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S1473-3099(22)00226-2","article-title":"Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial","volume":"22","author":"Bennett","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2026101419582247100_jiag284-B21","author":"Sattler"},{"key":"2026101419582247100_jiag284-B22","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1473-3099(25)00552-3","article-title":"More data needed on the FDA's decision to suspend Ixchiq [editorial]","volume":"25","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026101419582247100_jiag284-B23","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1473-3099(20)30238-3","article-title":"Single shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomized controlled trial","volume":"20","author":"Wressnigg","year":"2020","journal-title":"Lancet Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag284\/68435722\/jiag284.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/4\/508\/68435722\/jiag284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/4\/508\/68435722\/jiag284.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:58:30Z","timestamp":1792022310000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/234\/4\/508\/8698495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,5,30]]},"published-print":{"date-parts":[[2026,10,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag284","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,15]]},"published":{"date-parts":[[2026,5,30]]}}}